Liftstream is an executive search recruitment company in the life sciences sector
Genentech pays $150m for NewLink’s oncology drug
Authored by James Sheppard
Symphogen’s Monoclonal Antibody Technology Making Waves
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, antibody drug conjugate, clinical trials, conjugated mAb, epidermal growth factor receptor, Essex Woodland, European Society of Hematology, Genentech, hematology, Kirsten Drejer, Medicon Valley, Merck, monoclonal antibody, Novo A/S, oncology, Phase II, PKA, Roche, squamous cell carcinoma of the head & neck, SYM004, Symphogen
Leave a comment
Merus Biopharmaceuticals building to future with strong pipeline
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Acute Myeloid Leukaemia, Affitech, Aglaia Biomedical Ventures, Amsterdam Biotech, Astellas, Bay City Capital, bispecific, Charity, Crucell, Dr Setareh van Driel Shamsili, European Society of Hematology, funding, government, hematology, IND, Johnson & Johnson, Life Science Partners, London Biotech, London Innovation Centre, MCLA-117, Merus Biopharmaceuticals, Mr Jason Avery, Netherlands, Novartis Venture Fund, oncology, Pfizer, Series B funding, Ton Logtenberg
Leave a comment
Roche reaffirms commitment to Hematology Testing
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged anaemia, Bausch & Lomb, blood diseases, Bloodhound, Boston, Boston Biotech cluster, CMI, Constitution Medical Inc, COO, diagnostics, hematology, laboratory solutions, leukaemia, Roche, Roche Diagnostics, Roland Diggelmann, Valeant, Warburg Pincus
Leave a comment
Gilead Expands Oncology Offering with Purchase of YM Bioscience
In mid-December Gilead Sciences announced they had signed a deal to purchase the Canadian company YM Bioscience for $510m in cash ($2.95 per share). The purchase gives Gilead access to a second experimental drug to treat a rare blood and immune cell disorder.
Posted in Orphan Drugs and Rare Diseases
Tagged Gilead, hematology, oncology, YM Bioscience
Leave a comment